Journal
NATURE
Volume 537, Issue 7618, Pages 50-56Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nature19323
Keywords
-
Categories
Funding
- Biogen
Ask authors/readers for more resources
Alzheimer's disease (AD) is characterized by deposition of amyloid-beta (A beta) plaques and neurofibrillary tangles in the brain, accompanied by synaptic dysfunction and neurodegeneration. Antibody-based immunotherapy against A beta to trigger its clearance or mitigate its neurotoxicity has so far been unsuccessful. Here we report the generation of aducanumab, a human monoclonal antibody that selectively targets aggregated A beta. In a transgenic mouse model of AD, aducanumab is shown to enter the brain, bind parenchymal A beta, and reduce soluble and insoluble A beta in a dose-dependent manner. In patients with prodromal or mild AD, one year of monthly intravenous infusions of aducanumab reduces brain A beta in a dose- and time-dependent manner. This is accompanied by a slowing of clinical decline measured by Clinical Dementia Rating Sum of Boxes and Mini Mental State Examination scores. The main safety and tolerability findings are amyloid-related imaging abnormalities. These results justify further development of aducanumab for the treatment of AD. Should the slowing of clinical decline be confirmed in ongoing phase 3 clinical trials, it would provide compelling support for the amyloid hypothesis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available